Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Anika Therapeutics, Inc. operates as an integrated orthopedic medicines company. The Company develops, manufactures, and commercializes therapeutic pain management solutions based on its proprietary hyaluronic acid (HA) technology. Anika Therapeutics markets its products worldwide.
Website: anikatherapeutics.com



Growth: Bad revenue growth rate -33.3%, there is slowdown compared to average historical growth rates -5.5%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -75.8%. On average the margin is decreasing steadily. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.07 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -2.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 2.8% higher than minimum and 74.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -2.9x by EV / Sales multiple

Key Financials (Download financials)

Ticker: ANIK
Share price, USD:  (+1.5%)8.33
year average price 16.76  


year start price 25.01 2024-08-13

max close price 26.75 2024-08-19

min close price 8.10 2025-07-30

current price 8.33 2025-08-12
Common stocks: 14 364 000

Dividend Yield:  0.0%
EV / Sales: 0.7x
Margin (EBITDA LTM / Revenue): -75.8%
Fundamental value created in LTM:
Market Cap ($m): 120
Net Debt ($m): -30
EV (Enterprise Value): 90
Price to Book: 0.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-08-09globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anika Therapeutics, Inc. - ANIK

2025-08-06prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

2025-08-01globenewswire.com

Kirby McInerney LLP Announces Investigation Against Anika Therapeutics, Inc. (ANIK) on Behalf of Investors

2025-07-30zacks.com

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

2025-07-30globenewswire.com

Anika Reports Second Quarter 2025 Financial Results

2025-05-09zacks.com

Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates

2025-03-07globenewswire.com

Anika Completes Divestiture of Parcus Medical

2024-11-22globenewswire.com

Anika To Participate in December 2024 Investor Conferences

2024-11-02seekingalpha.com

Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript

2024-10-31zacks.com

Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437
fillingDate 2024-11-04 2024-08-08 2024-05-08 2024-03-15 2023-11-03 2023-08-08 2023-05-09 2023-03-16 2022-11-09
acceptedDate 2024-11-04 16:41:12 2024-08-08 17:21:03 2024-05-08 17:15:37 2024-03-15 12:20:07 2023-11-02 17:41:52 2023-08-08 17:15:17 2023-05-09 17:15:26 2023-03-16 15:37:56 2022-11-09 14:31:46
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 39M 42M 41M 43M 41M 44M 38M 40M 40M
costOfRevenue 37M 15M 16M 17M 17M 15M 15M 15M 17M
grossProfit 1M 27M 25M 26M 25M 29M 23M 24M 23M
grossProfitRatio 0.037 0.653 0.608 0.613 0.602 0.654 0.602 0.609 0.566
researchAndDevelopmentExpenses 7M 7M 8M 8M 8M 9M 8M 8M 7M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 19M 20M 22M 20M 25M 24M 27M 23M 21M
otherExpenses 3M 0 0 0 0 0 0 0 0
operatingExpenses 29M 27M 30M 28M 33M 33M 35M 31M 29M
costAndExpenses 67M 42M 46M 45M 49M 48M 50M 46M 46M
interestIncome 406 000 0 0 577 000 635 000 561 000 0 0 0
interestExpense 0 0 592 000 1M 0 561 000 539 000 276 000 436 000
depreciationAndAmortization 2M 2M 3M 4M 4M 4M 4M 4M 0
ebitda -25M 2M -2M 2M -8M -81 000 -9M -7M -6M
ebitdaratio -0.656 0.053 -0.061 0.047 -0.185 -0.002 -0.237 -0.168 -0.144
operatingIncome -28M 161 000 -5M -2M -8M -4M -13M -7M -6M
operatingIncomeRatio -0.723 0.004 -0.125 -0.037 -0.185 -0.082 -0.331 -0.168 -0.144
totalOtherIncomeExpensesNet 406 000 595 000 592 000 -62M 635 000 561 000 539 000 276 000 436 000
incomeBeforeTax -28M 756 000 -4M -63M -7M -3M -12M -6M -5M
incomeBeforeTaxRatio -0.712 0.018 -0.11 -1.471 -0.17 -0.069 -0.317 -0.161 -0.133
incomeTaxExpense 2M 844 000 43 000 -204 000 -463 000 -329 000 -2M -1M -1M
netIncome -30M -88 000 -5M -63M -7M -3M -10M -5M -4M
netIncomeRatio -0.772 -0.002 -0.111 -1.466 -0.159 -0.062 -0.273 -0.124 -0.104
eps -2.03 -0.006 -0.31 -4.3 -0.45 -0.19 -0.71 -0.34 -0.29
epsdiluted -2.03 -0.006 -0.31 -4.3 -0.45 -0.19 -0.71 -0.34 -0.29
weightedAverageShsOut 15M 15M 15M 15M 15M 15M 15M 15M 15M
weightedAverageShsOutDil 15M 15M 15M 15M 15M 15M 15M 15M 15M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437
fillingDate 2024-11-04 2024-08-08 2024-05-08 2024-03-15 2023-11-03 2023-08-08 2023-05-09 2023-03-16 2022-11-09
acceptedDate 2024-11-04 16:41:12 2024-08-08 17:21:03 2024-05-08 17:15:37 2024-03-15 12:20:07 2023-11-02 17:41:52 2023-08-08 17:15:17 2023-05-09 17:15:26 2023-03-16 15:37:56 2022-11-09 14:31:46
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 62M 63M 69M 73M 71M 65M 80M 86M 88M
shortTermInvestments 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 62M 63M 69M 73M 71M 65M 80M 86M 88M
netReceivables 28M 34M 32M 36M 35M 37M 31M 35M 34M
inventory 40M 51M 49M 46M 44M 43M 41M 40M 37M
otherCurrentAssets 6M 7M 9M 8M 8M 8M 9M 9M 9M
totalCurrentAssets 136M 155M 159M 163M 157M 152M 160M 170M 168M
propertyPlantEquipmentNet 72M 75M 74M 75M 75M 78M 79M 79M 78M
goodwill 8M 7M 7M 8M 7M 7M 7M 7M 7M
intangibleAssets 3M 4M 4M 5M 69M 71M 73M 75M 77M
goodwillAndIntangibleAssets 11M 11M 12M 12M 76M 78M 80M 82M 83M
longTermInvestments 0 -1 0 5M 0 0 0 0 0
taxAssets 1M 1M 1M 1M 1M 1M 2M 1M 0
otherNonCurrentAssets 11M 20M 18M 14M 19M 19M 18M 17M 18M
totalNonCurrentAssets 95M 108M 105M 107M 171M 177M 179M 180M 180M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 231M 263M 264M 271M 328M 329M 339M 349M 348M
accountPayables 7M 10M 10M 10M 8M 8M 9M 9M 8M
shortTermDebt 2M 2M 2M 2M 2M 2M 2M 2M 2M
taxPayables 82 000 77 000 1M 1M 819 000 931 000 889 000 810 000 0
deferredRevenue 0 77 000 1M 1M -2M -2M 0 0 0
otherCurrentLiabilities 16M 14M 15M 18M 20M 16M 18M 17M 16M
totalCurrentLiabilities 25M 26M 28M 31M 28M 23M 29M 28M 26M
longTermDebt 25M 26M 26M 27M 27M 28M 28M 29M 29M
deferredRevenueNonCurrent 0 0 0 -16M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 16M 2M 3M 4M 6M 7M
otherNonCurrentLiabilities 806 000 407 000 403 999 403 999 400 000 401 000 399 000 398 000 26M
totalNonCurrentLiabilities 26M 26M 27M 27M 30M 31M 33M 36M 36M
otherLiabilities 0 0 1 1 0 0 0 0 0
capitalLeaseObligations 28M 28M 26M 27M 27M 30M 30M 29M 29M
totalLiabilities 52M 52M 55M 58M 58M 55M 61M 64M 63M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 147 000 148 000 148 000 147 000 146 000 147 000 147 000 146 000 146 000
retainedEarnings 94M 123M 124M 128M 191M 198M 200M 211M 216M
accumulatedOtherComprehensiveIncomeLoss -6M -6M -6M -6M -7M -6M -6M -6M -7M
othertotalStockholdersEquity 92M 93M 91M 90M 86M 82M 83M 81M 77M
totalStockholdersEquity 180M 210M 209M 212M 270M 274M 278M 286M 285M
totalEquity 180M 210M 209M 212M 270M 274M 278M 286M 285M
totalLiabilitiesAndStockholdersEquity 231M 263M 264M 271M 328M 329M 339M 349M 348M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 231M 263M 264M 271M 328M 329M 339M 349M 348M
totalInvestments 0 -1 0 5M 0 0 0 0 0
totalDebt 28M 28M 28M 29M 27M 30M 30M 31M 29M
netDebt -35M -35M -40M -44M -43M -35M -49M -55M -59M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437
fillingDate 2024-11-04 2024-08-08 2024-05-08 2024-03-15 2023-11-03 2023-08-08 2023-05-09 2023-03-16 2022-11-09
acceptedDate 2024-11-04 16:41:12 2024-08-08 17:21:03 2024-05-08 17:15:37 2024-03-15 12:20:07 2023-11-02 17:41:52 2023-08-08 17:15:17 2023-05-09 17:15:26 2023-03-16 15:37:56 2022-11-09 14:31:46
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -30M -88 000 -5M -63M -7M -3M -10M -5M -4M
depreciationAndAmortization 2M 2M 3M 4M 4M 4M 4M 4M 3M
deferredIncomeTax -184 000 17 000 193 000 -2M -1M -904 000 -2M -2M -1M
stockBasedCompensation 3M 4M 4M 4M 4M 4M 4M 4M 4M
changeInWorkingCapital 12M -8M -4M -3M 3M -14M 642 000 -2M -3M
accountsReceivables 5M -2M 4M -1M 2M -6M 4M -647 000 -2M
inventory -3M -5M -4M -3M -2M -3M -3M -3M -2M
accountsPayables -3M 148 000 401 000 1M -290 000 -316 000 -713 000 1M 249 000
otherWorkingCapital 13M -2M -4M 324 000 4M -4M 361 000 -311 000 1M
otherNonCashItems 18M 15M 11M 64M 4M 1M 1M 2M 4M
netCashProvidedByOperatingActivities 5M -1M -126 000 4M 6M -8M -4M 481 000 3M
investmentsInPropertyPlantAndEquipment -1M -3M -2M -2M -741 000 -1M -1M -3M -2M
acquisitionsNet 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0
otherInvestingActivites -600 000 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites -2M -3M -2M -2M -741 000 -1M -1M -3M -2M
debtRepayment 0 0 0 0 0 0 0 0 -231 000
commonStockIssued 0 0 23 000 335 000 0 486 000 0 0 0
commonStockRepurchased -4M -1M -2M 7000 -110 000 -5M 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -22 000 -205 000 -2M 7000 -110 000 -429 000 -2M 667 000 -4M
netCashUsedProvidedByFinancingActivities -4M -1M -2M 342 000 -110 000 -5M -2M 667 000 -5M
effectOfForexChangesOnCash 337 000 -224 000 -31 000 76 000 -54 000 27 000 30 000 -69 000 -22 000
netChangeInCash -454 000 -6M -4M 2M 6M -15M -7M -1M -4M
cashAtEndOfPeriod 62M 63M 69M 73M 71M 65M 80M 86M 88M
cashAtBeginningOfPeriod 63M 69M 73M 71M 65M 80M 86M 88M 91M
operatingCashFlow 5M -1M -126 000 4M 6M -8M -4M 481 000 3M
capitalExpenditure -1M -3M -2M -2M -741 000 -1M -1M -3M -2M
freeCashFlow 4M -4M -2M 2M 6M -10M -5M -2M 1M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-02 ET (fiscal 2024 q3)
2024 q2
2024-08-11 ET (fiscal 2024 q2)
2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-03-13 ET (fiscal 2023 q4)
2023 q3
2023-11-03 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-13 ET (fiscal 2023 q1)
2022 q4
2023-03-06 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-06 ET (fiscal 2022 q2)
2022 q1
2022-05-07 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-31 11:05 ET
Anika Reports Third Quarter 2024 Financial Results
2024-10-31 11:00 ET
Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical
2024-10-17 20:01 ET
Anika Announces Third Quarter 2024 Results Conference Call Date
2024-10-04 20:01 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-09 20:45 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-15 20:01 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-08 20:05 ET
Anika Reports Second Quarter 2024 Financial Results
2024-08-05 20:01 ET
Anika to Participate in the Sidoti Virtual Investor Conference
2024-07-25 13:00 ET
Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024
2024-07-16 11:19 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-07-11 12:30 ET
Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
2024-06-07 20:01 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-28 20:05 ET
Anika Enters into Cooperation Agreement with Caligan Partners
2024-05-08 20:08 ET
Anika Announces CFO Transition
2024-05-08 20:05 ET
Anika Reports First Quarter 2024 Financial Results
2024-05-03 20:01 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-18 20:01 ET
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
2024-04-02 12:00 ET
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2024-03-13 20:05 ET
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
2024-03-08 21:01 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-27 21:01 ET
Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
2024-02-13 14:00 ET
Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting
2023-11-28 14:00 ET
Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release
2023-11-07 21:05 ET
Anika to Participate in Upcoming Investor Conferences
2023-11-02 20:05 ET
Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business
2023-10-10 13:00 ET
Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023
2023-09-19 13:00 ET
Anika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting
2023-09-15 20:01 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-12 13:00 ET
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
2023-08-17 22:20 ET
Anika Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs
2023-08-08 20:05 ET
Anika Reports Second Quarter 2023 Financial Results
2023-07-20 20:05 ET
Anika to Issue Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
2023-07-12 13:00 ET
Anika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual Meeting
2023-05-30 20:05 ET
Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone
2023-05-09 20:05 ET
Anika Reports First Quarter 2023 Financial Results
2023-04-19 12:30 ET
Anika to Issue First Quarter 2023 Financial Results on Tuesday, May 9, 2023
2023-04-13 21:00 ET
Anika Enters Into Cooperation Agreement with Caligan Partners
2023-04-12 13:00 ET
Anika to Participate in the 22nd Annual Needham Virtual Healthcare Conference
2023-04-03 13:00 ET
Anika Continues to Expand Addressable Market for Tactoset® Injectable Bone Substitute with Additional 510(k) Clearance from FDA
2023-03-27 12:55 ET
Anika Files Preliminary Proxy Statement
2023-03-15 20:01 ET
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
2023-03-08 15:00 ET
Anika Highlights Products in High Growth Segments of Joint Preservation during the 2023 AAOS Annual Meeting
2023-03-06 21:05 ET
Anika Reports Fourth Quarter and Year-End Fiscal 2022 Financial Results
2023-02-28 14:00 ET
Anika to Participate in the Canaccord Genuity Musculoskeletal Conference
2023-02-21 15:30 ET
Anika to Issue Fourth Quarter and Year-End 2022 Financial Results on Monday, March 6, 2023
2023-02-21 15:00 ET
Anika Issues Statement
2023-02-21 13:00 ET
Caligan Partners Issues Open Letter to Anika Board
2023-02-13 13:30 ET
Anika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United States
2022-11-08 21:05 ET
Anika Reports Third Quarter Fiscal 2022 Financial Results
2022-11-01 12:00 ET
Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study
2022-10-25 13:25 ET
Anika to Issue Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
2022-09-12 20:01 ET
Anika Announces First Surgeries Performed Using the X-Twist™ Fixation System and Commences Limited Market Release
2022-08-03 20:05 ET
Anika Reports Second Quarter Fiscal 2022 Financial Results
2022-07-27 13:15 ET
Anika Receives the ACE Award for Cutting-Edge Innovation for Tactoset® Injectable Bone Substitute from the American Orthopedic Society for Sports Medicine
2022-07-12 21:05 ET
Anika to Issue Second Quarter 2022 Financial Results on Wednesday, August 3, 2022
2022-06-10 13:27 ET
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
2022-05-20 11:00 ET
Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio
2022-05-13 21:00 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-05-09 20:05 ET
Anika to Participate in the UBS Global Healthcare Conference 2022
2022-05-05 20:05 ET
Anika Reports First Quarter Fiscal 2022 Financial Results
2022-04-15 21:00 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-07 20:05 ET
Anika to Issue First Quarter 2022 Financial Results on Thursday, May 5, 2022
2022-04-04 20:05 ET
Anika to Participate in the 21st Annual Needham Virtual Healthcare Conference
2022-03-23 12:30 ET
Anika to Showcase its Transformation into a Global Leader in Joint Preservation during the 2022 AAOS Annual Meeting
2022-03-15 23:00 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-03-10 21:05 ET
Anika to Participate in the Canaccord Genuity Musculoskeletal Conference
2022-03-08 21:05 ET
Anika Reports Fourth Quarter and Year-End 2021 Financial Results
2022-02-11 23:50 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-02-08 21:01 ET
Anika to Issue Fourth Quarter and Year-End 2021 Financial Results on Tuesday, March 8, 2022
2021-12-10 22:00 ET
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-11-18 21:01 ET
Anika to Participate in Upcoming Investor Conferences
2021-11-04 20:05 ET
Anika Reports Third Quarter 2021 Financial Results
2021-11-01 13:00 ET
Anika Appoints Sheryl Conley to Board of Directors
2021-10-18 13:00 ET
Anika to Issue Third Quarter 2021 Financial Results on Thursday, November 4, 2021
2021-09-30 13:00 ET
Anika Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting
2021-09-14 13:00 ET
Tactoset® Injectable Bone Substitute Now FDA Cleared for Hardware Augmentation
2021-09-07 14:00 ET
Anika to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
2021-09-01 14:05 ET
Anika to Debut Joint Preservation Portfolio at the 2021 AAOS Annual Meeting
2021-08-05 20:05 ET
Anika Reports Second Quarter 2021 Financial Results
2021-07-19 14:00 ET
Anika to Issue Second Quarter 2021 Financial Results on Thursday, August 5, 2021
2021-07-01 13:00 ET
First Anika WristMotion® Total Wrist Arthroplasty Surgery Performed
2021-06-03 12:00 ET
Anika Hosts 2021 Virtual Investor Day
2021-05-13 15:00 ET
Anika to Host its 2021 Virtual Investor Day on June 3, 2021
2021-05-06 20:05 ET
Anika Reports First Quarter 2021 Financial Results
2021-05-04 14:30 ET
Anika to Participate in Upcoming Virtual Investor Conferences
2021-04-15 21:15 ET
Anika to Issue First Quarter 2021 Financial Results on Thursday, May 6, 2021
2021-04-05 13:25 ET
Anika to Participate in the 20th Annual Needham Virtual Healthcare Conference
2021-03-11 17:15 ET
Anika to Participate in the Sidoti Spring Virtual Investor Conference
2021-03-04 21:05 ET
Anika Reports Fourth Quarter and Year-End 2020 Financial Results
2021-02-09 20:00 ET
Anika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021
2020-11-04 21:05 ET
Anika Reports Third-Quarter 2020 Financial Results
2020-10-22 20:05 ET
Anika to Issue Third Quarter 2020 Financial Results and Business Highlights on Wednesday, November 4, 2020
2020-10-21 20:05 ET
Anika Announces FDA 510(k) Clearance for its WristMotion® Total Arthroplasty System for the Replacement of Painful Wrist Joints
2020-09-08 20:53 ET
Anika Announces Appointment of Jack Henneman and Stephen Richard to Board of Directors
2020-09-03 18:34 ET
Anika to Participate in Upcoming Virtual Investor Conferences
2020-08-05 20:09 ET
Anika Appoints Michael Levitz as Chief Financial Officer
2020-07-30 20:05 ET
Anika Reports Second Quarter 2020 Financial Results
2020-07-20 11:00 ET
Anika To Launch Six FDA-Cleared Sports Medicine and Extremities Products in Third Quarter of 2020
2020-07-16 20:05 ET
Anika to Issue Second Quarter 2020 Financial Results and Business Highlights on Thursday, July 30
2020-06-02 20:05 ET
Anika Announces Planned CFO Transition
2020-05-12 20:05 ET
Anika to Participate in 2020 UBS Virtual Global Healthcare Conference
2020-05-07 20:05 ET
Anika Reports First Quarter 2020 Financial Results
2020-04-27 12:30 ET
Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer
2020-04-23 20:05 ET
Anika to Issue First Quarter 2020 Financial Results and Business Highlights on Thursday, May 7
2020-04-08 20:05 ET
Anika Takes Actions to Strengthen Liquidity in Light of COVID-19
2020-03-04 13:30 ET
Anika Appoints David Colleran as General Counsel
2020-02-20 21:05 ET
Anika Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-12 21:05 ET
Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO
2020-02-06 21:05 ET
CORRECTING and REPLACING Anika to Issue Fourth-Quarter and Full-Year 2019 Financial Results and Business Highlights on Thursday, February 20
2020-02-03 21:30 ET
Anika Therapeutics Closes Acquisition of Arthrosurface
2020-01-29 21:30 ET
Anika Therapeutics Mourns the Sudden Passing of Joseph Darling, President and Chief Executive Officer
2020-01-24 21:05 ET
Anika Therapeutics Closes Acquisition of Parcus Medical
2020-01-13 20:00 ET
Sale of Global Leader in Joint Preservation Incubated at Primo Medical Group
2020-01-06 13:30 ET
Anika Therapeutics to Acquire Parcus Medical and Arthrosurface
2019-12-10 13:30 ET
Anika Commences Full U.S. Commercial Launch of TACTOSET Bone Repair Therapy at Orthopaedic Summit 2019: Evolving Techniques
2019-11-15 13:30 ET
Anika Therapeutics Announces Participation in MEDICA International Trade Fair and International Cartilage Regeneration and Joint Preservation Society Focus Meeting
2019-10-24 20:05 ET
Anika Reports Third Quarter 2019 Financial Results
2019-10-16 12:30 ET
Anika to Showcase Joint Preservation and Restoration Portfolio at the Annual Scientific Meeting of the International Society for Hip Arthroscopy
2019-10-14 12:30 ET
Anika Appoints Mira Leiwant as Vice President of Regulatory Affairs, Quality, and Clinical Affairs
2019-10-10 20:05 ET
Anika to Issue Third-quarter 2019 Financial Results and Business Highlights on Thursday, October 24
2019-10-04 12:30 ET
Anika to Showcase Joint Preservation and Restoration Portfolio at the 2019 World Congress of the International Cartilage Regeneration and Joint Preservation Society
2019-09-18 12:30 ET
Anika Commences U.S. Commercial Launch of TACTOSET Bone Repair Therapy Under Its New U.S. Hybrid Commercial Model

SEC forms

Show financial reports only

SEC form 10
2025-07-30 20:12 ET
Anika Therapeutics reported for 2025 q2
SEC form 8
2025-07-30 11:21 ET
Anika Therapeutics published news for 2025 q2
SEC form 8
2025-07-30 11:21 ET
Anika Therapeutics published news for 2025 q2
SEC form 8
2025-07-30 11:15 ET
Anika Therapeutics published news for 2025 q2
SEC form 8
2025-07-30 11:15 ET
Anika Therapeutics published news for 2025 q2
SEC form 10
2025-05-09 18:30 ET
Anika Therapeutics reported for 2025 q1
SEC form 8
2025-05-09 11:20 ET
Anika Therapeutics published news for 2025 q1
SEC form 8
2025-05-09 11:20 ET
Anika Therapeutics published news for 2025 q1
SEC form 10
2025-05-09 00:00 ET
Anika Therapeutics published news for 2025 q1
SEC form 10
2025-03-17 00:00 ET
Anika Therapeutics published news for 2024 q4
SEC form 8
2025-03-12 20:10 ET
Anika Therapeutics published news for 2024 q4
SEC form 8
2025-03-12 20:10 ET
Anika Therapeutics reported for 2024 q4
SEC form 10
2024-11-04 16:41 ET
Anika Therapeutics reported for 2024 q3
SEC form 8
2024-10-31 07:20 ET
Anika Therapeutics published news for 2024 q3
SEC form 8
2024-10-31 07:20 ET
Anika Therapeutics published news for 2024 q3
SEC form 10
2024-08-08 17:21 ET
Anika Therapeutics published news for 2024 q2
SEC form 8
2024-08-08 16:10 ET
Anika Therapeutics reported for 2024 q2
SEC form 8
2024-08-08 16:10 ET
Anika Therapeutics published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Anika Therapeutics published news for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Anika Therapeutics reported for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Anika Therapeutics published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Anika Therapeutics published news for 2024 q1
SEC form 10
2024-03-15 12:20 ET
Anika Therapeutics published news for 2023 q4
SEC form 10
2024-03-15 00:00 ET
Anika Therapeutics published news for 2023 q4
SEC form 8
2024-03-13 16:10 ET
Anika Therapeutics reported for 2023 q4
SEC form 8
2024-03-13 16:10 ET
Anika Therapeutics published news for 2023 q4
SEC form 10
2023-11-03 00:00 ET
Anika Therapeutics published news for 2023 q3
SEC form 10
2023-11-02 17:41 ET
Anika Therapeutics published news for 2023 q3
SEC form 8
2023-11-02 16:11 ET
Anika Therapeutics reported for 2023 q3
SEC form 10
2023-08-08 17:15 ET
Anika Therapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:11 ET
Anika Therapeutics published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Anika Therapeutics published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Anika Therapeutics published news for 2023 q2
SEC form 6
2023-06-21 16:50 ET
Anika Therapeutics published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Anika Therapeutics published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Anika Therapeutics published news for 2023 q1
SEC form 10
2023-03-16 00:00 ET
Anika Therapeutics reported for 2022 q4
SEC form 8
2023-03-06 00:00 ET
Anika Therapeutics reported for 2022 q4
SEC form 10
2022-11-09 00:00 ET
Anika Therapeutics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Anika Therapeutics reported for 2022 q3
SEC form 10
2022-08-04 00:00 ET
Anika Therapeutics reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Anika Therapeutics reported for 2022 q2
SEC form 10
2022-05-06 00:00 ET
Anika Therapeutics reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Anika Therapeutics reported for 2022 q1
SEC form 10
2022-03-11 00:00 ET
Anika Therapeutics published news for 2021 q4
SEC form 8
2022-03-08 00:00 ET
Anika Therapeutics published news for 2021 q4
SEC form 10
2021-11-05 00:00 ET
Anika Therapeutics published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Anika Therapeutics published news for 2021 q3
SEC form 10
2021-08-06 00:00 ET
Anika Therapeutics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Anika Therapeutics published news for 2021 q2
SEC form 10
2021-05-07 00:00 ET
Anika Therapeutics published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Anika Therapeutics published news for 2021 q1